Compare BUR & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BUR | VCEL |
|---|---|---|
| Founded | 2009 | 1989 |
| Country | Guernsey | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2017 | 1996 |
| Metric | BUR | VCEL |
|---|---|---|
| Price | $7.87 | $32.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $18.00 | ★ $58.50 |
| AVG Volume (30 Days) | ★ 2.1M | 527.5K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | 0.28 | ★ 0.32 |
| Revenue | ★ $413,360,000.00 | $276,259,000.00 |
| Revenue This Year | $73.95 | $19.10 |
| Revenue Next Year | $12.15 | $17.95 |
| P/E Ratio | ★ $27.63 | $98.34 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $7.61 | $29.24 |
| 52 Week High | $14.61 | $48.75 |
| Indicator | BUR | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 41.53 |
| Support Level | $7.61 | $31.24 |
| Resistance Level | $9.73 | $38.48 |
| Average True Range (ATR) | 0.32 | 1.34 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 25.13 | 36.04 |
Burford Capital Ltd is a finance firm providing litigation finance, insurance, and risk transfer, law firm lending, corporate intelligence and judgment enforcement, and a wide range of investment activities. It operates in two segments: Principal Finance, which allocates capital to legal finance assets from its balance sheet, primarily as capital provision assets and in limited scope through interests in private funds managed by the company; Asset management and other services, which includes the provision of services to the legal industry, including litigation insurance; and other corporate. The geographical segments include the United States, United Kingdom, Singapore, Hong Kong, China, and, Australia.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.